Provider Economics Drive Oncologist Consolidation

Article

Provider Economics Drive Oncologist Consolidation

March 08, 2024
Authors
Topics

Welcome to the March 2024 edition of our Monthly Insight Series. This month we examine the trend of oncologists consolidating into IDNs and network aggregators.

A stethoscope on a small pile of dollar bills.

Most oncologists now practice in either an integrated delivery network (IDN) or in a sophisticated medical group within a network of community practices. Declining economics drove this consolidation as larger entities with economic scale and bargaining power against suppliers and payers acquired practices and hired individual oncologists. Consequently, only 1 in 5 oncologists now practice in an independent community setting. The figure below illustrates the types of organizations where medical oncologists now practice.

Number of Medical Oncologists by Practice Setting, 2023 chart
  • IDNs/hospitals employ most medical oncologists: More than 60% of medical oncologists are employed in an IDN or hospital setting, providing them with quality-of-life benefits and a (more or less) stable financial status. As IDNs grow their oncology service lines, they represent an increasing threat to community practices – more than half of practices in our 2023 Community Oncology Survey cited IDNs as their major source of competition for referrals.
  • Oncology “network aggregators” are rapidly increasing in size: These aggregators, or large networks of community practices, have grown rapidly over the past 2-3 years and now employ nearly half of the oncologists remaining in community settings. Many aggregators are focusing on expanding their networks, and their numbers are expected to surpass that of independent community practices in the next few years. 
  • Independent community oncology practices can still be lucrative: Our upcoming landscape report dives into exclusive data on community practices’ revenues and expenses and illustrates independent groups’ economic realities, including the upsides. Practices that understand their competitive landscape and actively make strategic decisions to improve their positioning and revenue streams see the most success. Those that are operated as sophisticated businesses and look to gain economies of scale, including expansion through acquisitions in their market or contiguous markets, will remain competitive.
     

The Latest

Our 2024-2025 Oncology Clinical Pathways Report, set for release in December, will provide insights into the most impactful pathways and key factors manufacturers should assess as the oncology pathways landscape continues to evolve.
Article
Unlocking Oncology Pathway Impact: Beyond Lives Covered to Real Prescribing Influence

As Oncology pathway programs continue to become more prominent in the marketplace, manufacturers are being challenged to assess how influential a specific pathway is.

Daniel Buchenberger
Podcast
Community Oncology Practice Economics - Podcast Part 3 of 3

In the final part of this 3-part podcast series, HMP Executive Vice President Lee Blansett and special guest John Hennessy—health system, provider and oncology strategist—explore emerging models for success in oncology practice economics.

Lee Blansett
Bispecific Antibodies: A Balancing Act of Promise and Complexity
Article
Bispecific Antibodies: A Balancing Act of Promise and Complexity

Bispecific antibodies have emerged with great promise, but adoption has been slower than expected. This was a key topic discussed by a panel of 5 experts at the October 2024 Association for Value-Based Cancer Care (AVBCC) conference.

Chris Van Denburg